Pantomath Group announces first closing of pre-IPO fund, India Inflection Opportunity Fund ("IIOF" or "Fund"), with target to raise INR 500 crores (plus additional green shoe of INR 250 Crore) in its maiden close-ended series. Simultaneous to the first closing, the Fund has confirmed to have made its first investment as well, demonstrating the steady opportunity line-up.
IIOF, a category II Alternate Investment Fund ('AIF'), is managed by Pantomath Capital Management Private Limited. The Fund aims to harness opportunity of investing at pre-IPO stage in Indian growth stage businesses that are on the verge of a big bang breakout, thus investing with clear focus of value arbitrage (without taking long term risk). The Fund shall invest in diverse pre-IPO opportunities, aligned with India's rising economy, in three broad themes: (a) Make in India; (b) Rural Consumption, and (c) Impact investing.
The Fund has announced its first closing of about 25% of its target corpus, with participation by marquee anchor investor(s). The Fund has received investment participation from global & domestic family offices and high net-worth investors.
"India Inflection Opportunity Fund is focused on under-penetrated businesses with established foundation and visible growth trajectory. We would like to focus on huge addressable market opportunity avoiding ventures with negative cash flows and bleeding balance sheets. Our India Inflection Opportunity Fund will provide the growth capital to various enterprises through active ownership approach" remarks, Ms. Madhu Lunawat, Fund Manager.
Ms. Madhu Lunawat has over two decades of rich experience spanning across investment management, corporate finance, asset reconstruction, M&A, due diligence and treasury operations. By qualification, Madhu is a rank-holder Chartered Accountant and CFA Level II (AIMR, USA). Prior to founding Pantomath, Madhu worked with leading corporates, viz., Infosys, ASREC and Edelweiss. A quick decision maker, straight forward and no-tolerance manager, Madhu is known for her picks as also exits.
The Fund has made its first investment alongside the first closing, in a specialty chemical CSM company, Inventys Research Company Private Limited ("Inventys").
Inventys is a research driven specialty chemical company with focus on custom synthesis & manufacturing (CSM). The Company's product portfolio comprises advanced intermediates, actives in agro-chem and pharma. Inventys has developed capabilities of critically complex chemistries, backed by 6 state-of-the-art manufacturing plants and R&D facility at Nagpur spread across 7 acres. The plants are fully backward integrated up to widely available intermediates, mitigating China dependency. The Company has acquired 17 acres of additional land which can house 30 additional plants. Inventys caters to large global MNC innovator customer base and possesses long term business relationship with them. Handling highly complex multi-step synthesis backed by world-class R&D and advanced flow chemistry process engineering, the Company presents extreme high entry and exit barriers to trade.
Speaking on this, Ms. Madhu Lunawat remarked, "We were impressed by the depth, speed & execution capabilities of Inventys team. We are glad to participate in a company like Inventys, which is run by extremely professional and highly learned promoters with long-standing impeccable business relationships with global giants. Representing a true 'made in India and make for the world' solution for global markets, substituting imports and fostering exports, Inventys scores optimum in our Fund parameters of inflection opportunities making impact."
The Fund has distinguished investment strategy coupled with periodic payouts to investors, besides targeting healthy terminal returns. Deloitte is the statutory auditor of the Fund. The Fund has eminent Board of Advisors too. |
